CY1123222T1 - Χρηση των υποδοχεων ccr3 - Google Patents
Χρηση των υποδοχεων ccr3Info
- Publication number
- CY1123222T1 CY1123222T1 CY20201100678T CY201100678T CY1123222T1 CY 1123222 T1 CY1123222 T1 CY 1123222T1 CY 20201100678 T CY20201100678 T CY 20201100678T CY 201100678 T CY201100678 T CY 201100678T CY 1123222 T1 CY1123222 T1 CY 1123222T1
- Authority
- CY
- Cyprus
- Prior art keywords
- eosinophilic
- alkyl
- macular degeneration
- solar
- syndrome
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Ophthalmology & Optometry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Otolaryngology (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Structure Of Transmissions (AREA)
Abstract
Η παρούσα εφεύρεση αναφέρεται σε αναστολείς CCR3 του Χημικού Τύπου (Ι), όπου το R1 είναι Η, C1-6-αλκύλιο, C0-4-αλκύλιο, C3-6-κυκλοαλκύλιο, C1-6-αλογονοαλκύλι, το R2 είναι Η, C1-6-αλκύλιο, το Χ είναι ένα ανιόν που επιλέγεται από την ομάδα που αποτελείται από χλωριούχο ή 1/2 τρυγικό διβενζοϋλεστέρα, το j είναι 1 ή 2, για χρήση ως φάρμακο για τη θεραπεία νόσων που επιλέγονται από ξηρή ηλιακή εκφύλιση της ωχράς κηλίδας (dAMD), υγρή ηλιακή εκφύλιση της ωχράς κηλίδας (WAMD), πρόωρη αμφιβληστροειδοπάθεια (ROP), απόφραξη κεντρικής φλεβικής αμφιβληστροειδούς (CRVO), ρινική πολύποση, ηωσινοφιλική οισοφαγίτιδα, ηωσινοφιλική γαστρεντερίτιδα (π.χ. ηωσινοφιλική γαστρίτιδα και ηωσινοφιλική εντερτερίτιδα), υπερηωσινοφιλικό σύνδρομο και σύνδρομο Churg Strauss.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12162937 | 2012-04-03 | ||
| PCT/EP2013/056864 WO2013149986A1 (en) | 2012-04-03 | 2013-04-02 | Use of ccr3-inhibitors |
| EP13713199.1A EP2833884B1 (en) | 2012-04-03 | 2013-04-02 | Use of ccr3-inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1123222T1 true CY1123222T1 (el) | 2021-10-29 |
Family
ID=48040249
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20201100678T CY1123222T1 (el) | 2012-04-03 | 2020-07-23 | Χρηση των υποδοχεων ccr3 |
Country Status (27)
| Country | Link |
|---|---|
| US (5) | US20130261153A1 (el) |
| EP (3) | EP2833884B1 (el) |
| JP (2) | JP2015512432A (el) |
| KR (4) | KR20200044988A (el) |
| CN (2) | CN110384699A (el) |
| AU (1) | AU2013245027B2 (el) |
| BR (1) | BR112014023795B1 (el) |
| CA (1) | CA2869269C (el) |
| CL (1) | CL2014002523A1 (el) |
| CY (1) | CY1123222T1 (el) |
| DK (1) | DK2833884T3 (el) |
| EA (1) | EA032263B1 (el) |
| ES (1) | ES2811554T3 (el) |
| HR (1) | HRP20201165T1 (el) |
| HU (1) | HUE051648T2 (el) |
| IL (1) | IL234262A (el) |
| IN (1) | IN2014DN06989A (el) |
| LT (1) | LT2833884T (el) |
| MX (1) | MX2014011786A (el) |
| NZ (1) | NZ628882A (el) |
| PH (1) | PH12014502239A1 (el) |
| PL (1) | PL2833884T3 (el) |
| PT (1) | PT2833884T (el) |
| RS (1) | RS60665B1 (el) |
| SI (1) | SI2833884T1 (el) |
| WO (1) | WO2013149986A1 (el) |
| ZA (1) | ZA201406082B (el) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8278302B2 (en) | 2009-04-08 | 2012-10-02 | Boehringer Ingelheim International Gmbh | Substituted piperidines as CCR3 antagonists |
| UA109290C2 (uk) | 2010-10-07 | 2015-08-10 | Спільні кристали і солі інгібіторів ccr3 | |
| AR090566A1 (es) | 2012-04-02 | 2014-11-19 | Boehringer Ingelheim Int | Proceso para la produccion de inhibidores de crr |
| US20130261153A1 (en) * | 2012-04-03 | 2013-10-03 | Boehringer Ingelheim International Gmbh | Use of ccr3-inhibitors |
| US10213421B2 (en) | 2012-04-04 | 2019-02-26 | Alkahest, Inc. | Pharmaceutical formulations comprising CCR3 antagonists |
| JP6684363B2 (ja) | 2016-11-24 | 2020-04-22 | キリシマ精工株式会社 | 歯列矯正具 |
| CN110636844A (zh) | 2017-04-05 | 2019-12-31 | 万能溶剂有限公司 | 使用ccr3-抑制剂治疗衰老相关损伤的方法及组合物 |
| JP7179755B2 (ja) * | 2017-04-05 | 2022-11-29 | アルカヘスト インコーポレイテッド | Ｃｃｒ３阻害剤を使用した網膜関連疾患を治療するための方法および組成物 |
| KR20200067859A (ko) * | 2017-10-13 | 2020-06-12 | 알카헤스트 인코포레이티드 | Ccr3-억제제를 사용한 소양증, 건조증, 및 관련 질환을 치료하기 위한 방법 및 조성물 |
| AU2019271122A1 (en) | 2018-05-15 | 2020-11-12 | Alkahest, Inc. | Treatment of aging-associated disease with modulators of leukotriene A4 hydrolase |
| AU2019346456A1 (en) * | 2018-09-26 | 2021-04-15 | Alkahest, Inc. | Methods and compositions for treating aging-associated impairments using CCR3-inhibitors |
| US20230312697A1 (en) * | 2020-06-11 | 2023-10-05 | Alkahest Inc. | Methods of improving retina-associated disease outcome using ccr3-inhibitors |
| AU2022376563A1 (en) | 2021-11-01 | 2023-12-07 | Alkahest, Inc. | Benzodioxane modulators of leukotriene a4 hydrolase (lta4h) for prevention and treatment of aging-associated diseases |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6339087B1 (en) * | 1997-08-18 | 2002-01-15 | Syntex (U.S.A.) Llc | Cyclic amine derivatives-CCR-3 receptor antagonists |
| MXPA02008472A (es) * | 2000-03-03 | 2004-03-26 | Cambridge Antibody Tech | Anticuerpos humanos contra la eotaxina y su uso. |
| US20020151064A1 (en) * | 2001-02-07 | 2002-10-17 | Children's Hospital Medical Center | Regulation of CCR3 expression |
| US8030003B2 (en) * | 2004-12-07 | 2011-10-04 | Children's Hospital Medical Center | Diagnosis of eosinophilic esophagitis based on presence of an elevated level of eotaxin-3 |
| US8008092B2 (en) * | 2007-10-09 | 2011-08-30 | University Of Kentucky Research Foundation | CCR3 inhibition for ocular angiogenesis and macular degeneration |
| WO2010069979A1 (en) * | 2008-12-16 | 2010-06-24 | Nycomed Gmbh | Pyran derivatives as ccr3 modulators |
| EP2236520A1 (en) * | 2009-03-31 | 2010-10-06 | Leukocare Ag | Stabilizing composition for immobilized biomolecules |
| US8278302B2 (en) | 2009-04-08 | 2012-10-02 | Boehringer Ingelheim International Gmbh | Substituted piperidines as CCR3 antagonists |
| WO2010138591A1 (en) * | 2009-05-26 | 2010-12-02 | University Of Kentucky Research Foundation | Ccr3 and its ligands are therapeutic and diagnostic targets for neovascular age-related macular degeneration |
| UA109290C2 (uk) * | 2010-10-07 | 2015-08-10 | Спільні кристали і солі інгібіторів ccr3 | |
| US20130261153A1 (en) * | 2012-04-03 | 2013-10-03 | Boehringer Ingelheim International Gmbh | Use of ccr3-inhibitors |
| US10213421B2 (en) * | 2012-04-04 | 2019-02-26 | Alkahest, Inc. | Pharmaceutical formulations comprising CCR3 antagonists |
| WO2020115836A1 (ja) * | 2018-12-05 | 2020-06-11 | 東浜工業株式会社 | ブロワー装置 |
-
2013
- 2013-03-27 US US13/851,564 patent/US20130261153A1/en not_active Abandoned
- 2013-04-02 KR KR1020207011392A patent/KR20200044988A/ko active Application Filing
- 2013-04-02 EA EA201401083A patent/EA032263B1/ru unknown
- 2013-04-02 PL PL13713199T patent/PL2833884T3/pl unknown
- 2013-04-02 KR KR1020147027679A patent/KR20140144200A/ko active Application Filing
- 2013-04-02 CN CN201910406245.7A patent/CN110384699A/zh active Pending
- 2013-04-02 CA CA2869269A patent/CA2869269C/en active Active
- 2013-04-02 DK DK13713199.1T patent/DK2833884T3/da active
- 2013-04-02 RS RS20200868A patent/RS60665B1/sr unknown
- 2013-04-02 SI SI201331753T patent/SI2833884T1/sl unknown
- 2013-04-02 EP EP13713199.1A patent/EP2833884B1/en active Active
- 2013-04-02 NZ NZ628882A patent/NZ628882A/en unknown
- 2013-04-02 JP JP2015503847A patent/JP2015512432A/ja active Pending
- 2013-04-02 CN CN201380016333.7A patent/CN104220073A/zh active Pending
- 2013-04-02 MX MX2014011786A patent/MX2014011786A/es unknown
- 2013-04-02 KR KR1020217015686A patent/KR20210063481A/ko not_active IP Right Cessation
- 2013-04-02 LT LTEP13713199.1T patent/LT2833884T/lt unknown
- 2013-04-02 PT PT137131991T patent/PT2833884T/pt unknown
- 2013-04-02 HU HUE13713199A patent/HUE051648T2/hu unknown
- 2013-04-02 AU AU2013245027A patent/AU2013245027B2/en active Active
- 2013-04-02 EP EP20174399.4A patent/EP3763369B1/en active Active
- 2013-04-02 WO PCT/EP2013/056864 patent/WO2013149986A1/en active Application Filing
- 2013-04-02 BR BR112014023795-6A patent/BR112014023795B1/pt active IP Right Grant
- 2013-04-02 KR KR1020227031439A patent/KR20220132012A/ko not_active Application Discontinuation
- 2013-04-02 IN IN6989DEN2014 patent/IN2014DN06989A/en unknown
- 2013-04-02 EP EP24158785.6A patent/EP4389217A3/en active Pending
- 2013-04-02 ES ES13713199T patent/ES2811554T3/es active Active
-
2014
- 2014-08-19 ZA ZA2014/06082A patent/ZA201406082B/en unknown
- 2014-08-24 IL IL234262A patent/IL234262A/en active IP Right Grant
- 2014-09-24 CL CL2014002523A patent/CL2014002523A1/es unknown
- 2014-10-03 PH PH12014502239A patent/PH12014502239A1/en unknown
- 2014-12-15 US US14/570,298 patent/US20150099783A1/en not_active Abandoned
-
2015
- 2015-11-30 US US14/953,480 patent/US20160081998A1/en not_active Abandoned
-
2017
- 2017-07-25 US US15/658,918 patent/US20170319567A1/en not_active Abandoned
- 2017-12-22 JP JP2017246173A patent/JP2018080183A/ja not_active Withdrawn
-
2020
- 2020-07-23 CY CY20201100678T patent/CY1123222T1/el unknown
- 2020-07-27 HR HRP20201165TT patent/HRP20201165T1/hr unknown
- 2020-08-19 US US16/997,772 patent/US20200375971A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1123222T1 (el) | Χρηση των υποδοχεων ccr3 | |
| CY1122601T1 (el) | Αναστολεις gsk3 και μεθοδοι χρησης αυτων | |
| CY1122712T1 (el) | ΧΡΗΣΗ ΠΑΡΑΓΩΓΩΝ ΠΥΡΑΖΟΛΟΠΥΡΙΜΙΔΙΝΗΣ ΓΙΑ ΤΗ ΘΕΡΑΠΕΙΑ ΣΧΕΤΙΚΩΝ ΜΕ PI3Kδ ΔΙΑΤΑΡΑΧΩΝ | |
| CY1119707T1 (el) | Ενωσεις διαρυλικου αμιδιου ως αναστολεις της κινασης | |
| CY1123988T1 (el) | Ενωση πυριδινης | |
| CY1124311T1 (el) | Παρεμποδιστες dna-pk | |
| CY1124000T1 (el) | Υποκατεστημενες 5-φθορο-1η-πυραζολοπυριδινες σε κρυσταλλικη μορφη | |
| CY1118969T1 (el) | Ενωσεις πυριμιδινο-2-αμινης και η χρηση τους ως αναστολεις των κινασων jak | |
| CY1119056T1 (el) | Παραγωγα 2',4',-διφθορο-2'-μεθυλ υποκατεστημενου νουκλεοσιδιου ως αναστολεις αντιγραφης hcv rna | |
| CY1119058T1 (el) | Ενωσεις ιμιδαζοπυρρολιδινονης | |
| CY1121695T1 (el) | Ενωσεις και συνθεσεις ως αναστολεις κινασης c-kit | |
| CY1120334T1 (el) | Υποκατεστημενης 3-αλλογονοαλυλαμινης αναστολεις ssao και χρησεις αυτων | |
| CY1122275T1 (el) | Μεσεγχυματικα στρωματικα κυτταρα και χρησεις που σχετιζονται με αυτα | |
| CY1119433T1 (el) | Αμινο-υποκατεστημενες ιμιδαζοπυριδαζινες | |
| UY34451A (es) | Derivados de uracilo como inhibidores de la quinasa axl y c-met | |
| CY1118135T1 (el) | Παραγωγα 2-(φαινυλο ή πυριδ-3-υλο) αμινοπυριμιδινης ως ρυθμιστες κινασης lrrk2 για τη θεραπευτικη αντιμετωπιση της νοσου του parkinson | |
| CR20120591A (es) | Derivados de aminopirimidina como moduladores de la lrrk2 | |
| EA201790323A1 (ru) | Ингибиторы протеинкиназы c и способы их применения | |
| CY1121137T1 (el) | Φαρμακευτικα σκευασματα που περιλαμβανουν ανταγωνιστες ccr3 | |
| EA201590881A1 (ru) | Терапевтические соединения и композиции и их использование в качестве модуляторов пк-m2 | |
| AR089781A1 (es) | Fluorometil-5,6-dihidro-4h-[1,3]oxazinas | |
| CY1123216T1 (el) | Αναστολεις της gls1 για την αντιμετωπιση νοσων | |
| ECSP17007336A (es) | Compuestos de imidazopiridazina | |
| EA201891262A1 (ru) | Фармацевтическая композиция, содержащая производные глутаримидов, их применение для лечения эозинофильных заболеваний | |
| CR20150211A (es) | Compuestos diméricos |